SCHEMBL19852212

SCHEMBL19852212

c1ccc(OC2CCN(CCOc3ccc4cccnc4c3)CC2)cc1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 1/20 0.51
SLC6A2 P23975 2/20 0.50
SLC6A4 P31645 2/20 0.50
CYP3A4 P08684 1/20 0.49
DRD3 P35462 1/20 0.48
CARM1 Q86X55 1/20 0.47
PRMT6 Q96LA8 1/20 0.47
HRH3 Q9Y5N1 2/20 0.46
HTR1A P08908 3/20 0.45
PDE10A Q9Y233 2/20 0.44
TMEM97 Q5BJF2 1/20 0.44
SIGMAR1 Q99720 1/20 0.44
PDE3B Q13370 1/20 0.44
PDE3A Q14432 1/20 0.44
CYP2D6 P10635 1/20 0.44
MEN1 O00255 1/20 0.43
MAPT P10636 1/20 0.43
KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19852211 0.96 DRD2 (0.49) DRD2SLC6A2SLC6A4CYP3A4DRD3
SCHEMBL19852514 0.80 PDE10A (0.53) CYP3A4DRD3HRH3HTR1APDE10A
SCHEMBL18322904 0.77 GSK3B (0.42) DRD2DRD3CARM1PRMT6HRH3
SCHEMBL19852049 0.76 HRH3 (0.65) DRD2SLC6A4DRD3CARM1PRMT6
SCHEMBL14937684 0.76 CYP3A4 (0.69) CYP3A4DRD3PDE10AMEN1MAPT
SCHEMBL30997262 0.76 HRH3 (0.61) DRD3HRH3
SCHEMBL9826117 0.75 DRD3 (0.76) DRD2SLC6A2SLC6A4CYP3A4DRD3
SCHEMBL1893865 0.74 LTA4H (0.71)
SCHEMBL23412137 0.73 CYP3A4 (0.68) CYP3A4DRD3PDE10AMEN1MAPT
SCHEMBL6652253 0.73 DRD3 (0.58) DRD3HRH3SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11186564-B2 Dual NAV1.2/5HT2a inhibitors for treating CNS disorders SUNOVION PHARMACEUTICALS INC. (US) 2021-11-30 US disclosed
US-11186564-B2 Dual NAV1.2/5HT2a inhibitors for treating CNS disorders SUNOVION PHARMACEUTICALS INC. (US) 2021-11-30 US disclosed
US-20190194163-A1 DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS SUNOVION PHARMACEUTICALS INC. (US) 2019-06-27 US disclosed
US-20190194163-A1 DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS SUNOVION PHARMACEUTICALS INC. (US) 2019-06-27 US disclosed
WO-2018026371-A1 DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS SUNOVION PHARMACEUTICALS INC. (US) 2018-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190194163-A1 DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS SCN2A, HTR2A, HTR2C DRD2 69/4885SLC6A2 5/4885SLC6A4 15/4885
US-11186564-B2 Dual NAV1.2/5HT2a inhibitors for treating CNS disorders SCN2A, HTR2A, HTR2C DRD2 69/4885SLC6A2 5/4885SLC6A4 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.